Post-Doc position in preclinical imaging and radiochemistry available at the Center for Cancer Research of Marseille (CRCM) in the Prostate Cancer Group. The position is based at the Institut Paoli Calmettes (IPC) campus and funded by Aix-Marseille University Excellence Initiative for 24 months, with possible options for renewable and/or future recruitment by Inserm and CNRS. The salary is dependent on the candidate’s experience.
The selected candidate will be responsible to carrying experiments to develop a novel nucleolipids-based nanocarrier functionalized with targeting moieties (PMSA) for co-delivering radionuclides and antisense oligonucleotide against Hsp27 (OGX-427) in order to improve anti-tumor effects molecular radiotherapy in PCa. The experiments will be carried out in the molecular oncology team of the CRCM, in the biopathology department of IPC, and in the European Center for Research in Medical Imaging (CERIMED).
Candidates should be very motivated and have expertise in preclinical imaging (especially with small animals dedicated SPECT/CT and PET/CT) and radiochemistry.
The selected candidate will be responsible to develop pre-clinical evaluation of using nanovectorized antisens in castrate-resistant prostate cancer models in order to licence 3 related international patents with industrial partner. The selected candidate will manage master and PhD students that will work on the project. This work is done in collaboration with Pr. Philippe Barthelemy (ChemBioMed, INSERM U869, Bordeaux) and is funded by Aix-Marseille University Excellence Initiative.
Expected start date: April 2018.